A Systematic Review of the Gastrointestinal Microbiome: A Game Changer in Colorectal Cancer

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Oct 3

PMID 36185901

Authors

Aziza K Eastmond

Chaitra Shetty

Syed Muhammad Hannan Ali Rizvi

Joudi Sharaf

Kerry-Ann D Williams

Maha Tariq

Maitri V Acharekar

Sara Elena Guerrero Saldivia

Sumedha Unnikrishnan

Yeny Y Chavarria

Adebisi O Akindele

Ana P Jalkh

Prachi Balani

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a malignant condition of the colon and rectum. Generally, malignancies constitute a significant health threat to humans, and the result can be devastating. CRC is no exception. The gastrointestinal (GI) microbiome has long been suspected of impacting CRC. This review seeks to explore whether there is a connection between the two or not. For screening purposes, relevant articles were culled from various databases using key terms and phrases. Following a thorough search, the inclusion and exclusion criteria were applied, and a quality assessment was conducted. The articles retained were comprehensively studied, and revealed imbalances of the GI microbiome do indeed exhibit an association with CRC.

Citing Articles

Friend or Foe: Exploring the Relationship between the Gut Microbiota and the Pathogenesis and Treatment of Digestive Cancers.

Profir M, Rosu O, Cretoiu S, Gaspar B Microorganisms. 2024; 12(5).

PMID: 38792785 PMC: 11124004. DOI: 10.3390/microorganisms12050955.

Gut Microbiota and Colorectal Cancer: An Umbrella Review of Methodological Trends and Clinical Correlations.

Kasagga A, Hawrami C, Ricci E, Hailu K, Salib K, Savithri Nandeesha S Cureus. 2024; 16(2):e54210.

PMID: 38496101 PMC: 10942869. DOI: 10.7759/cureus.54210.

The role of microbiomes in gastrointestinal cancers: new insights.

Yarahmadi A, Afkhami H Front Oncol. 2024; 13:1344328.

PMID: 38361500 PMC: 10867565. DOI: 10.3389/fonc.2023.1344328.

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.

Abenavoli L, Montori M, Svegliati Baroni G, Argenziano M, Giorgi F, Scarlata G Medicina (Kaunas). 2023; 59(8).

PMID: 37629716 PMC: 10456509. DOI: 10.3390/medicina59081427.

Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis.

Cazzaniga M, Zonzini G, DI Pierro F, Moricoli S, Bertuccioli A Int J Mol Sci. 2022; 23(20).

PMID: 36293390 PMC: 9604377. DOI: 10.3390/ijms232012538.

References

Ernst M, Putoczki T . Targeting IL-11 signaling in colon cancer. Oncotarget. 2013; 4(11):1860-1. PMC: 3875751. DOI: 10.18632/oncotarget.1410. View

Wirbel J, Pyl P, Kartal E, Zych K, Kashani A, Milanese A . Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019; 25(4):679-689. PMC: 7984229. DOI: 10.1038/s41591-019-0406-6. View

Yang Y, Misra B, Liang L, Bi D, Weng W, Wu W . Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics. 2019; 9(14):4101-4114. PMC: 6592169. DOI: 10.7150/thno.35186. View

Lucas C, Barnich N, Nguyen H . Microbiota, Inflammation and Colorectal Cancer. Int J Mol Sci. 2017; 18(6). PMC: 5486131. DOI: 10.3390/ijms18061310. View

Zhang Y, Yu X, Yu E, Wang N, Cai Q, Shuai Q . Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study. BMC Microbiol. 2018; 18(1):92. PMC: 6114884. DOI: 10.1186/s12866-018-1232-6. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View

Coker O, Nakatsu G, Dai R, Wu W, Wong S, Ng S . Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut. 2018; 68(4):654-662. PMC: 6580778. DOI: 10.1136/gutjnl-2018-317178. View

Yu J, Feng Q, Wong S, Zhang D, Liang Q, Qin Y . Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2015; 66(1):70-78. DOI: 10.1136/gutjnl-2015-309800. View

Peters B, Dominianni C, Shapiro J, Church T, Wu J, Miller G . The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome. 2017; 4(1):69. PMC: 5203720. DOI: 10.1186/s40168-016-0218-6. View

10.

Alhinai E, Walton G, Commane D . The Role of the Gut Microbiota in Colorectal Cancer Causation. Int J Mol Sci. 2019; 20(21). PMC: 6862640. DOI: 10.3390/ijms20215295. View

11.

Zhang S, Kong C, Yang Y, Cai S, Li X, Cai G . Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer. Theranostics. 2020; 10(25):11595-11606. PMC: 7545992. DOI: 10.7150/thno.49515. View

12.

Osman M, Neoh H, Mutalib N, Chin S, Mazlan L, Ali R . Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Sci Rep. 2021; 11(1):2925. PMC: 7859180. DOI: 10.1038/s41598-021-82465-0. View

13.

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

14.

Chen Z, Hsieh Y, Huang C, Tsai C . Inhibitory Effects of Probiotic Lactobacillus on the Growth of Human Colonic Carcinoma Cell Line HT-29. Molecules. 2017; 22(1). PMC: 6155858. DOI: 10.3390/molecules22010107. View

15.

Gagniere J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E . Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016; 22(2):501-18. PMC: 4716055. DOI: 10.3748/wjg.v22.i2.501. View